Previous 10 | Next 10 |
PARSIPPANY, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 Barclays Global Healthcare Conference at 9:00 AM ET on Thursday, March 12, 2020. Live audio of the event can be accessed by visiting the “E...
Investment Thesis Pacira BioSciences ( PCRX ) is capitalising on a growing trend - led by the Centers for Medicaid and Medicare ("CMS") - away from opioid-related treatments and making significant headway with its opioid-free extended release local anesthetic exparel - a combination of local...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
Pacira BioSciences, Inc. (PCRX) Q4 2019 Earnings Conference Call February 20, 2020 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participan...
Pacira BioSciences ( PCRX ) Q4 results : More news on: Pacira BioSciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Pacira Pharmaceuticals (NASDAQ: PCRX ): Q4 Non-GAAP EPS of $0.56 beats by $0.12 ; GAAP EPS of -$0.12 misses by $0.26 . More news on: Pacira BioSciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Full-year 2019 revenue increases 25 percent to $421 million versus 2018 — — Total 2020 revenue guidance of between $485 million and $500 million — — Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth — ...
Pacira Pharmaceuticals (NASDAQ: PCRX ) is scheduled to announce Q4 earnings results on Thursday, February 20th, before market open. The consensus EPS Estimate is $0.44 (-6.4% Y/Y) and the consensus Revenue Estimate is $122.04M (+28.3% Y/Y). Over the last 2 years, PCRX has beaten EPS e...
PARSIPPANY, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results before the open of the U.S. markets on Thursday, February 20, 2020. Following the release, the...
IVERIC bio (NASDAQ: ISEE ) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company. More news on: IVERIC bio, Inc., Matinas BioPharma Holdings, Inc., Pacira BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule...
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement...
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...